It's OK, we all knew the truth deep down anyway.
Correction to our earlier post: Wymer, Lehner et al. found HoLEP was most cost-effective for BPH in 30–80 and 80–150 cc prostates using a decision model. Patient preferences may change rankings.View quoted post on X
@vidit_sharma_ @SocietyofBPD
doi.org/10.1016/j.urol…